Nordion's deal with Sterigenics clears U.S. antitrust hurdle
July 11 (Reuters) - Nordion Inc , a Canadian supplier of medical isotopes, said it had cleared a U.S. antitrust hurdle, paving the way for the company to be acquired by Sterigenics.
The U.S. Federal Trade Commission terminated the waiting period for the acquisition under the Hart-Scott-Rodino Antitrust Improvements Act, Nordion said in a statement.
The company said in June it had received a request for additional information from the U.S. regulator.
Nordion also said on Friday that it received a no-action letter from the Canadian Competition Bureau.
The deal is expected to close in the second half of this year.
Nordion is a leading producer of molybdenum-99, an isotope used in medical imaging, while Sterigenics is a sterilization services provider owned by private equity firm GTCR LLC.
Nordion's U.S.-listed shares were up 3 percent at $12.80 in premarket trading. (Reporting by Ashutosh Pandey in Bangalore; Editing by Kirti Pandey)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Two dead, including gunman, in shooting at Washington high school: police
- U.S. officials considering quarantines for returning healthcare workers |
- New York police officer critically wounded in hatchet attack |
- Putin accuses United States of damaging world order